《盈警響號》永勝醫療(01612.HK)料上半年盈轉虧 蝕最多4,500萬元
永勝醫療(01612.HK)公佈,預期截至6月底止上半年可能錄得未經審覈綜合虧損淨額介乎4,000萬至4,500萬元,而去年同期則錄綜合溢利約4,190萬元。
公司指出,期內錄得綜合虧損淨額主要由於集團呼吸產品分部的表現未如早前所預測,故相關存貨的流動速度遠低於集團所預期。經審慎評估,以及考慮到市場的各種不確定因素、存貨剩餘價值以及集團呼吸產品分部的預期表現,公司於期內就滯銷及/或陳舊存貨作出撥備約4,300萬元;於疫情的一次性影響逐漸減弱的前提下,上半年呼吸產品分部收入按年減少40.5%。
此外,由於集團旗下呼吸產品的銷量及產量均有所下降,產品組合變動以及集團錄得的固定生產經常性開支及直接成本導致其毛利率下降。中國及其他國家採取不同防疫措施,加上全球物流運力不足和物流成本急升,令集團的毛利率進一步受壓。該等因素抵銷產品價格上漲及生產成本效益提高所帶來的正面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.